An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Not Recruiting

Trial ID: NCT04433858

Age - 18 Years-65 Years Gender - All Accepting Healthy Volunteers - No

Purpose

The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.

Official Title

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Stanford Investigator(s)

Trisha Suppes, MD, PhD
Trisha Suppes, MD, PhD

Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)

Eligibility


Inclusion Criteria:

   - Diagnosis of at least moderate Major Depressive Disorder (MDD)

Exclusion Criteria:

   - Comorbidities

Note for CA sites: Only Veterans are Eligible

View More
View Less

Intervention(s):

drug: Psilocybin

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

©2024 Stanford Medicine